BioCentury | Jun 29, 2017
Translation in Brief

Toolbox upgrade

...the antitumor activity of T cells bearing low affinity T cell receptors (TCRs). Since acquiring Trianta Immunotherapies GmbH...
BioCentury | Apr 11, 2016
Clinical News

DC Vaccine containing WT1/PRAME: Phase I/II started

...which will be paid in Medigene shares, to former shareholders of Trianta Immunotherapies GmbH . Medigene acquired Trianta...
BioCentury | Aug 17, 2015
Finance

Medigene remade

...when survival was the goal. Staying alive Although Medigene's entire research engine has roots in Trianta Immunotherapies GmbH...
...for big pharma. We cannot step into the same role as big pharma." Trying with Trianta...
...and in 2014 ended up buying a company located about two blocks away - Trianta. Trianta...
BioCentury | Jul 17, 2014
Financial News

Medigene raises EUR 15.9 million

...T cell immunotherapy programs, which the company gained through its acquisition earlier this year of Trianta Immunotherapies GmbH...
BioCentury | May 5, 2014
Company News

Medigene management update

...Germany Business: Cancer, Autoimmune, Infectious Hired: Dolores Schendel as CSO, while remaining managing director at Trianta Immunotherapies GmbH...
BioCentury | Feb 3, 2014
Company News

Medigene, Trianta deal

...Medigene acquired Trianta in a deal worth up to €9.5 million ($13.1 million). Trianta was spun...
...cell receptors to treat T cell leukemias and autoimmune disease. In connection with the deal, Trianta...
...Director Dolores Schendel will join Medigene as CSO, effective May 1 (see BioCentury, Jan. 20). Trianta...
BioCentury | Feb 3, 2014
Finance

Highlights of weekly biotech stock moves

...treat advanced gastroesophageal cancer. Medigene AG (Xetra:MDG) gained €0.19 to €3.78 last week after acquiring Trianta Immunotherapies GmbH...
BioCentury | Jan 28, 2014
Company News

Medigene acquires cancer immunotherapy play Trianta

...acquired Trianta Immunotherapies GmbH (Planegg-Martinsried, Germany) in a deal worth up to EUR 9.5 million ($13.1 million). Trianta...
...mAbs that directly target T cell receptors to treat T cell leukemias and autoimmune disease. Trianta...
...close of EUR 3.60 on Friday, the last trading day before the deal was announced. Trianta...
BioCentury | Jan 20, 2014
Company News

Trianta, Helmholtz Zentrum Muenchen, Max Delbrueck Center for Molecular Medicine Berlin-Buch deal

...The Max Delbrueck Center and Helmholtz Zentrum Muenchen granted newco Trianta exclusive, worldwide rights to IP...
...an undisclosed equity stake in Trianta. Helmholtz Zentrum Muenchen spun off Trianta in late 2013. Trianta...
...tumor-specific T cells and trigger both T cells and NK cells to attack cancer cells. Trianta...
Items per page:
1 - 9 of 9
BioCentury | Jun 29, 2017
Translation in Brief

Toolbox upgrade

...the antitumor activity of T cells bearing low affinity T cell receptors (TCRs). Since acquiring Trianta Immunotherapies GmbH...
BioCentury | Apr 11, 2016
Clinical News

DC Vaccine containing WT1/PRAME: Phase I/II started

...which will be paid in Medigene shares, to former shareholders of Trianta Immunotherapies GmbH . Medigene acquired Trianta...
BioCentury | Aug 17, 2015
Finance

Medigene remade

...when survival was the goal. Staying alive Although Medigene's entire research engine has roots in Trianta Immunotherapies GmbH...
...for big pharma. We cannot step into the same role as big pharma." Trying with Trianta...
...and in 2014 ended up buying a company located about two blocks away - Trianta. Trianta...
BioCentury | Jul 17, 2014
Financial News

Medigene raises EUR 15.9 million

...T cell immunotherapy programs, which the company gained through its acquisition earlier this year of Trianta Immunotherapies GmbH...
BioCentury | May 5, 2014
Company News

Medigene management update

...Germany Business: Cancer, Autoimmune, Infectious Hired: Dolores Schendel as CSO, while remaining managing director at Trianta Immunotherapies GmbH...
BioCentury | Feb 3, 2014
Company News

Medigene, Trianta deal

...Medigene acquired Trianta in a deal worth up to €9.5 million ($13.1 million). Trianta was spun...
...cell receptors to treat T cell leukemias and autoimmune disease. In connection with the deal, Trianta...
...Director Dolores Schendel will join Medigene as CSO, effective May 1 (see BioCentury, Jan. 20). Trianta...
BioCentury | Feb 3, 2014
Finance

Highlights of weekly biotech stock moves

...treat advanced gastroesophageal cancer. Medigene AG (Xetra:MDG) gained €0.19 to €3.78 last week after acquiring Trianta Immunotherapies GmbH...
BioCentury | Jan 28, 2014
Company News

Medigene acquires cancer immunotherapy play Trianta

...acquired Trianta Immunotherapies GmbH (Planegg-Martinsried, Germany) in a deal worth up to EUR 9.5 million ($13.1 million). Trianta...
...mAbs that directly target T cell receptors to treat T cell leukemias and autoimmune disease. Trianta...
...close of EUR 3.60 on Friday, the last trading day before the deal was announced. Trianta...
BioCentury | Jan 20, 2014
Company News

Trianta, Helmholtz Zentrum Muenchen, Max Delbrueck Center for Molecular Medicine Berlin-Buch deal

...The Max Delbrueck Center and Helmholtz Zentrum Muenchen granted newco Trianta exclusive, worldwide rights to IP...
...an undisclosed equity stake in Trianta. Helmholtz Zentrum Muenchen spun off Trianta in late 2013. Trianta...
...tumor-specific T cells and trigger both T cells and NK cells to attack cancer cells. Trianta...
Items per page:
1 - 9 of 9